ATLANTA, GA., May 29, 2025 (GLOBE NEWSWIRE) -- Americold Realty Trust (NYSE: COLD), a global leader in temperature-controlled logistics, real estate and value-added services, today breaks ground in Port Saint John, New Brunswick, on its first import-export hub to be built in Canada. Provincial and local leaders join company executives to celebrate this significant investment in New Brunswick, a ceremony held in conjunction with Port Saint John’s Port Days. The new cold storage facility, to become the sixth ...

Geochemical survey completed confirming gas and oil presence in previous discoveries which will be the target of first well to be drilled by IEC at Citarum JAKARTA, INDONESIA AND DANVILLE, CA, May 29, 2025 (GLOBE NEWSWIRE) -- Indonesia Energy Corporation (NYSE American: INDO) ("IEC"), an oil and gas exploration and production company focused on Indonesia, today announced encouraging results from a regional geochemical survey conducted between September 2024 and March 2025 at IEC’s 195,000 acre Citarum Block ...

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Rezolve Ai (NASDAQ: RZLV), a global leader in AI-powered commerce technology, announced that its Chairman and Chief Executive Officer, Daniel M. Wagner, will participate in a fireside chat in the 2025 Virtual Tech Conference presented by Maxim Group LLC on Tuesday, June 3, 2025 at 1:00 p.m. Eastern Time. A link to the live session, which will be held on the M-Vest Platform and require conference registration, can be found at https://m-vest.com/events/tmt-06032025. ...

The combined entity supports healthcare organizations nationwide with an aggregate Net Patient Revenue of more than $300B and brings together best-in-class billing compliance and revenue integrity solutions to empower health systems with actionable foresight and end-to-end visibility. MDaudit to acquire all outstanding shares of Streamline stock for $5.34 per share in cash, a premium of 138% to Streamline’s closing price on May 28, 2025. Boston, Mass. and Atlanta, Ga., May 29, 2025 (GLOBE NEWSWIRE) -- MDau ...

WESTBROOK, Maine, May 29, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, announced today that Erik Shields has been named Vice President of Beverage of Synergy, effective May 26, 2025. “We’re excited to welcome Erik to the team and look forward to his contributions,” said Jack Ross, CEO of Synergy. “With nearly two decades of experience leading national strategies, managing key accounts, and building high-per ...

BOCA RATON, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Q.E.P. CO., INC. (OTCQX: QEPC) (the “Company” or “QEP”) today reported its financial results for the full fiscal year ended February 28, 2025. These results follow the completion of a portfolio transformation in fiscal 2024, which included the divestiture of the Company’s Harris Flooring Group and international operations in the United Kingdom, Australia, and New Zealand. These actions were taken to sharpen the Company’s strategic focus on its core North Am ...

Core Insights - illumin Holdings Inc. has launched a new Forecasting tool aimed at enhancing marketers' ability to plan and execute advertising campaigns with greater confidence and clarity [1][3] Product Features - The Forecasting tool is fully integrated within the illumin platform, providing a comprehensive, data-driven view of campaign potential prior to launch [2] - Unlike other platforms, illumin allows for simultaneous planning across multiple tactics and channels, including CTV, DOOH, and native advertising, while offering granular control over each media element [2] - The tool enables marketers to model the impact of individual media elements and consolidate them into a cohesive campaign forecast, offering clarity on audience reach, spend allocation, and strategic performance [2] Strategic Importance - The launch of the Forecasting tool reflects illumin's commitment to transforming programmatic advertising by equipping marketers with essential tools and insights for success in a data-driven media landscape [3] - The tool introduces flexibility and foresight into the planning process, empowering marketing teams to proceed with confidence [3] Company Overview - illumin is focused on evolving the digital advertising landscape by providing a customer-centric approach that allows brands and agencies to plan, build, and execute campaigns across various marketing channels within a single platform [4] - The company serves clients across North America, Latin America, and Europe, emphasizing a unified approach to digital advertising [4]

Core Insights - Alumis Inc. has completed patient enrollment in its pivotal Phase 3 ONWARD clinical program for ESK-001, targeting moderate-to-severe plaque psoriasis, with over 1,700 patients enrolled [2][4] - Topline results are expected to be reported in early Q1 2026, indicating progress towards providing new treatment options for patients [1][2] - ESK-001 is a next-generation oral TYK2 inhibitor designed to address immune dysregulation in various diseases, including plaque psoriasis [3][7] Clinical Program Details - The ONWARD clinical program consists of two parallel global Phase 3 trials, ONWARD1 and ONWARD2, each lasting 24 weeks and designed to evaluate the efficacy and safety of ESK-001 [4][5] - Patients are randomized in a 2:1:1 ratio to receive either ESK-001 40 mg twice daily, placebo, or apremilast, with co-primary endpoints focusing on the Psoriasis Area and Severity Index (PASI 75) and sPGA score [4][5] - An optional long-term extension trial, ONWARD3, is ongoing to assess the durability and long-term safety of ESK-001 for patients completing Week 24 [5] Product Profile - ESK-001 is characterized as a highly selective oral TYK2 inhibitor, aiming to minimize off-target effects while providing effective treatment for immune-mediated diseases [3][7] - The drug's development is supported by positive data from the Phase 2 STRIDE clinical trial and ongoing long-term open-label extensions [5] Broader Development Pipeline - Alumis is also exploring ESK-001's potential in other immune-mediated conditions, including a Phase 2b trial for systemic lupus erythematosus [6][7] - The company is developing a once-daily modified-release formulation of ESK-001 to enhance patient convenience compared to the current twice-daily regimen [5]

Core Insights - VCI Global Limited is developing Project QG, a next-generation infrastructure platform aimed at enabling sovereign AI deployment and encrypted data monetization for governments and institutions [1][4] - The global AI market is projected to exceed US$1.8 trillion by 2030, driven by enterprise adoption and the growth of AI-native infrastructure [2] - The cybersecurity and data protection market is expected to reach approximately US$298.5 billion by 2028, indicating a growing demand for secure data solutions [3] Project QG Overview - Project QG integrates AI-driven hardware encryption, zero-trust computing, and blockchain validation, positioning it as a foundational layer for future AI and data sovereignty [2] - The platform is designed for institutions that require sovereign-ready infrastructure to comply with data localization laws while maintaining control over their information [4] - VCI Global is currently engaging institutional stakeholders for early proof-of-concept pilots, with a full launch planned for Q3 2025 [5] Strategic Importance - The initiative addresses the underutilization of institutional and national datasets due to regulatory risks and privacy concerns, aiming to unlock value from sensitive data without compromising its integrity [6] - The convergence of AI, cybersecurity, and sovereign data economics places VCI Global at the forefront of this emerging market [4] - The company emphasizes the importance of monetizing proprietary data and software assets as a new revenue stream for enterprises [3]

PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer (“CMO”), effective June 9, 2025. Dr. Chagin succeeds Dr. Karen Smith, M.D., Ph.D., MBA, LLM, who has been serving as interim CMO and will remain a member of the Company’s Board of Directors (“Board”). Dr. C ...